|
Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide. |
|
|
Consulting or Advisory Role - Astellas Pharma; Dendreon; Janssen Oncology; Urogen pharma |
Speakers' Bureau - Astellas Pharma; Bayer; Blue Earth Diagnostics; Clovis Oncology; Genomic Health; Janssen Oncology; Merck; Pfizer |
Research Funding - Dendreon; Janssen Oncology; Myovant Sciences |
|
|
Consulting or Advisory Role - Janssen Scientific Affairs |
|
|
Employment - Janssen Scientific Affairs |
|
|
Consulting or Advisory Role - Janssen Scientific Affairs |
|
|
Employment - Janssen Scientific Affairs |
|
|
Consulting or Advisory Role - Janssen Scientific Affairs |
|
|
No Relationships to Disclose |
|
|
Employment - Janssen Scientific Affairs |
|
|
Consulting or Advisory Role - Janssen Scientific Affairs |